⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of ClearB Therapeutics, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
ClearB Therapeutics, Inc.
↗Concord, Massachusetts, USA
ClearB Therapeutics is a clinical-stage biotechnology company focused on developing therapeutic vaccines to achieve a functional cure for chronic hepatitis B (CHB) infection. The company's approach is grounded in proprietary insights derived from studying rare-event infection resolution in patients who have successfully cleared the virus.
Their lead candidate, CLB-4000, is a bivalent subunit therapeutic vaccine consisting of HBsAg variants (CLB-405 and CLB-505) combined with a novel saponin-based adjuvant, TQL-1055, licensed from Adjuvance Technologies. The company is currently evaluating this candidate in Phase 1b clinical trials.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Revenue:$1M-$5M
Founded:2017
Ownership:private
Status:operating
FUNDING
Stage:Venture Capital-Backed
Investors:Morningside Ventures
PIPELINE
Stage:Phase 1
Lead Drug Stage:Phase 1b
Modalities:Therapeutic vaccine, Subunit vaccine, mRNA
Active Trials:3
Trial Phases:Phase 1: 3
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Adjuvance Technologies (License for TQL-1055 adjuvant), Victoria Infectious Diseases Reference Laboratory (Founding collaboration)
COMPETITION
Position:Emerging
Competitors:Ultivue, Ohana Biosciences, Matterworks
LEADERSHIP
Key Executives:
Aileen Rubio - CEO
Aditi Deshpande - Project Lead / Scientist
Wendy Luca - Clinical Development
Scientific Founders:Professor Stephen Locarnini
LINKS
Website:clearbtherapeutics.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with ClearB Therapeutics, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.